AbbVie (NYSE:ABBV) Announces Earnings Results, Beats Estimates By $0.06 EPS

AbbVie (NYSE:ABBV) issued its quarterly earnings results on Wednesday. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06, FiscalAI reports. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the business posted $2.46 earnings per share. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie beat Q1 expectations with adjusted EPS of $2.65 and $15 billion in revenues, and raised full?year adjusted EPS guidance by $0.12 to $14.08–$14.28, citing stronger-than-expected demand across the portfolio.
• Immunology momentum remains a key driver—SKYRIZI sales were $4.5B (up ~29% operationally) and management now models ~$21.6B for 2026, while RINVOQ reached $2.1B (up ~20%) with a $10.2B full?year assumption, both outperforming expectations.
• Pipeline progress in gastroenterology was highlighted—subcutaneous induction SKYRIZI for Crohn’s was submitted in the U.S. with an approval decision expected later this year, and a combo of SKYRIZI + ABBV?382 showed ~42% endoscopic remission at week 24 in a highly refractory cohort, suggesting potentially transformational efficacy.
• Early-stage R&D catalysts include encouraging obesity data for the long?acting amylin analog ABBV?295 (~10% weight loss in 12 weeks, good tolerability) and an accelerated oncology plan with etentamig now expected to be submitted by year?end, both cited as near?term growth opportunities.
• The FDA issued a complete response letter for TrenibotE due to manufacturing questions (no safety/efficacy issues), delaying a U.S. approval path while international launches are still expected later this year.

AbbVie Price Performance

ABBV stock opened at $209.89 on Friday. AbbVie has a 1 year low of $176.57 and a 1 year high of $244.81. The firm has a market capitalization of $371.12 billion, a PE ratio of 103.41, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. The business has a 50 day simple moving average of $214.55 and a 200-day simple moving average of $221.60.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is 293.22%.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research analyst reports. Berenberg Bank set a $275.00 target price on AbbVie in a research note on Tuesday, January 20th. Guggenheim boosted their price target on shares of AbbVie from $242.00 to $249.00 and gave the stock a “buy” rating in a report on Friday, April 10th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Citigroup dropped their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Finally, Piper Sandler reduced their price target on shares of AbbVie from $299.00 to $294.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $252.90.

Insider Buying and Selling

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its stake in shares of AbbVie by 38.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 25,847 shares of the company’s stock valued at $5,906,000 after buying an additional 7,116 shares during the period. Strive Financial Group LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at approximately $216,000. Blue Sparrow LLC DE acquired a new position in AbbVie in the fourth quarter valued at approximately $28,561,000. Mercer Global Advisors Inc. ADV lifted its holdings in AbbVie by 5.9% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 430,631 shares of the company’s stock valued at $100,411,000 after acquiring an additional 23,859 shares during the last quarter. Finally, Summit Global Investments grew its position in AbbVie by 21.4% in the fourth quarter. Summit Global Investments now owns 16,916 shares of the company’s stock worth $3,865,000 after acquiring an additional 2,987 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and guidance raise: AbbVie reported Q1 revenue and EPS above estimates and raised its 2026 EPS outlook after strong performance from Skyrizi, Rinvoq and Botox — the core driver of today’s bullish move. Article Title
• Positive Sentiment: Bank of America upgrade: BofA upgraded ABBV to Buy (from Neutral) and lifted its target, citing Skyrizi strength and reduced concern about competitive erosion — this analyst action supports the rally. Article Title
• Positive Sentiment: Additional price-target lifts: Morgan Stanley and Canaccord among firms increasing their targets (Morgan Stanley to $278; Canaccord to $265), reinforcing upside expectations from Street analysts. Article Title
• Neutral Sentiment: Skyrizi competitive positioning: AbbVie outlined how Skyrizi will defend against J&J’s new plaque-psoriasis entrant (Icotyde); product durability/prescriber loyalty remain key watch items for future growth. Article Title
• Neutral Sentiment: Corporate PR / ecosystem work: AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), and Allergan Aesthetics launched a philanthropic program — positive for corporate image but unlikely to move near-term fundamentals. Article Title
• Negative Sentiment: Ongoing Humira decline and pipeline moves: Humira sales continue to fall (still a material legacy product) and AbbVie discontinued a cancer candidate — investors should watch how new blockbusters replace legacy revenue long-term. Article Title
• Negative Sentiment: Analyst estimate trim and insider selling: Erste trimmed FY2026/27 EPS projections slightly, and disclosed insider sales in recent months — these can cap multiple expansion and add caution for momentum traders. Article Title

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.